Fidelity Select Biotechnology Portfolio Total Revenue

The latest total revenue for FBIOX is $9.9M as of September 2023. That compares with $9.3M in the prior-year period — up 6.6% year over year. That is below the sector sector average of $1.2B. Investors often review this figure alongside Fidelity Select Biotechnology Portfolio's historical trend and sector peers before judging valuation or financial health.

Over the past year, FBIOX's total revenue moved from $9.3M to $9.9M — a 6.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fidelity Select Biotechnology Portfolio's operating scale or balance-sheet position.

Against its sector companies, FBIOX currently prints $9.9M for total revenue, while the sector average sits near $1.2B. That is roughly 99.2% below the sector mean. Large gaps often invite a closer look at Fidelity Select Biotechnology Portfolio's growth, margins, and balance sheet.

A total revenue figure of $9.9M for FBIOX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.2B. Explore the charts below for those layers of context.

After noting FBIOX's total revenue ($9.9M), review year-over-year change from $9.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.